Citations

Mayo Clinic

Showing 10 of 108602 citations.

The Effect of Foot Structure and Range of Motion on Musculoskeletal Overuse Injuries
Brodine, Stephanie K., Shaffer, Richard A., Johnson, Chrisanna Weech, Cullison, Thomas R., Kaufman, Kenton R.

The American Journal of Sports Medicine | July 19, 2017 | Volume: 27 | Issue: 5 | Pages: 585-593

10.1177/03635465990270050701 | PMID 10496574 Get It

The purpose of this prospective study was to determine whether an association exists between foot structure and the development of musculoskeletal overuse injuries. The study group was a well-defined cohort of 449 trainees at the Naval Special Warfare Training Center in Coronado, California. Before beginning training, measurements were made of ankle motion, subtalar motion, and the static (standing) and dynamic (walking) characteristics of the foot arch. The subjects were tracked prospectively for injuries throughout training. We identified risk factors that predispose people to lower extremity overuse injuries. These risk factors include dynamic pes planus, pes cavus, restricted ankle dorsiflexion, and increased hindfoot inversion, all of which are subject to intervention and possible correction.
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1–MAPK Interaction
Jin, Xin , Pan, Yunqian , Wang, Liguo , Zhang, Lizhi , Tang, Amy , Billadeau, Daniel D. , Wu, Heshui , Ma, Tao , Huang, Haojie , Wang, Liguo , Tang, Amy H , Jin, Xin

Cancer Research | July 18, 2017 | Volume: 77 | Issue: 16 | Pages: 4328-4341

10.1158/0008-5472.can-16-3143 | PMID 28720574 Get It

Abstract Dysregulation of the MAPK pathway correlates with progression of pancreatic ductal adenocarcinoma (PDAC) progression. IQ motif containing GTPase-activating protein 1 (IQGAP1) is a MAPK scaffold that directly regulates the activation of RAF, MEK, and ERK. Fructose-1,6-bisphosphatase (FBP1), a key enzyme in gluconeogenesis, is transcriptionally downregulated in various cancers, including PDAC. Here, we demonstrate that FBP1 acts as a negative modulator of the IQGAP1–MAPK signaling axis in PDAC cells. FBP1 binding to the WW domain of IQGAP1 impeded IQGAP1-dependent ERK1/2 phosphorylation (pERK1/2) in a manner independent of FBP1 enzymatic activity. Conversely, decreased FBP1 expression induced pERK1/2 levels in PDAC cell lines and correlated with increased pERK1/2 levels in patient specimens. Treatment with gemcitabine caused undesirable activation of ERK1/2 in PDAC cells, but cotreatment with the FBP1-derived small peptide inhibitor FBP1 E4 overcame gemcitabine-induced ERK activation, thereby increasing the anticancer efficacy of gemcitabine in PDAC. These findings identify a primary mechanism of resistance of PDAC to standard therapy and suggest that the FBP1–IQGAP1–ERK1/2 signaling axis can be targeted for effective treatment of PDAC. Cancer Res; 77(16); 4328–41. ©2017 AACR.
Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia
Yan, Fei , Pang, Jiuxia, Zhao, Na , Gangat, Naseema , Bode, Ann M. , Al‐Kali, Aref , Litzow, Mark R. , Liu, Shujun , Shen, Na , Wu, Lai‐Chu

Clinical Cancer Research | July 18, 2017 | Volume: 23 | Issue: 20 | Pages: 6254-6266

10.1158/1078-0432.ccr-17-0235 | PMID 28720666 Get It

Abstract Purpose: Receptor tyrosine kinases (RTKs) are frequently deregulated in leukemia, yet the biological consequences of this deregulation remain elusive. The mechanisms underlying aberrant methylation, a hallmark of leukemia, are not fully understood. Here we investigated the role of RTKs in methylation abnormalities and characterized the hypomethylating activities of RTK inhibitors. Experimental Design: Whether and how RTKs regulate expression of DNA methyltransferases (DNMTs), tumor suppressor genes (TSGs) as well as global and gene-specific DNA methylation were examined. The pharmacologic activities and mechanisms of actions of RTK inhibitors in vitro, ex vivo, in mice, and in nilotinib-treated leukemia patients were determined. Results: Upregulation of RTKs paralleled DNMT overexpression in leukemia cell lines and patient blasts. Knockdown of RTKs disrupted, whereas enforced expression increased DNMT expression and DNA methylation. Treatment with the RTK inhibitor, nilotinib, resulted in a reduction of Sp1-dependent DNMT1 expression, the diminution of global DNA methylation, and the upregulation of the p15INK4B gene through promoter hypomethylation in AML cell lines and patient blasts. This led to disruption of AML cell clonogenicity and promotion of cellular apoptosis without obvious changes in cell cycle. Importantly, nilotinib administration in mice and human patients with AML impaired expression of DNMTs followed by DNA hypomethylation, TSG re-expression, and leukemia regression. Conclusions: Our findings demonstrate RTKs as novel regulators of DNMT-dependent DNA methylation and define DNA methylation status in AML cells as a pharmacodynamic marker for their response to RTK-based therapy, providing new therapeutic avenues for RTK inhibitors in overcoming epigenetic abnormalities in leukemia. Clin Cancer Res; 23(20); 6254–66. ©2017 AACR.
Intrinsically disordered chromatin protein NUPR1 binds to the C-terminal region of Polycomb RING1B
Santofimia‐Castaño, Patricia , Rizzuti, Bruno , Pey, Ángel L. , Soubeyran, Philippe , Vidal, Miguel , Neira, José L. , Urrutia, Raúl , Iovanna, Juan , Santofimia-Castaño, Patricia

Proceedings of the National Academy of Sciences | July 18, 2017 | Volume: 114 | Issue: 31 | Pages: No page available

10.1073/pnas.1619932114 | PMID 28720707 Get It

Significance We describe the interaction between an intrinsically disordered protein (IDP), NUPR1, and the well-folded C-terminal region of RING1B protein of the Polycomb complex, involving residues Ala33 and Thr68 of the IDP. These observations are significant because they raise the possibility that NUPR1 aids the function of the members of the Polycomb complex, playing an active role in carcinogenesis.
Advances in Collaborative Care
Williams, Mark D. , Katzelnick, David J.

Focus | July 18, 2017 | Volume: 15 | Issue: 3 | Pages: 243-243

10.1176/appi.focus.20170025 | PMID 31975853 Get It

Systematic Case Review in Integrated Care
Katzelnick, David J.

Focus | July 18, 2017 | Volume: 15 | Issue: 3 | Pages: 292-293

10.1176/appi.focus.20170019 | PMID 31975860 Get It

The Role of Integrated Care in Managing Chronic Pain
Leasure, William B. , Leasure, Emily L.

Focus | July 18, 2017 | Volume: 15 | Issue: 3 | Pages: 284-291

10.1176/appi.focus.20170014 | PMID 31975859 Get It

Evidence-Based Psychotherapy in Primary Care
Sawchuk, Craig N. , Craner, Julia R.

Focus | July 18, 2017 | Volume: 15 | Issue: 3 | Pages: 264-270

10.1176/appi.focus.20170010 | PMID 31975856 Get It

Developing the Business Case and Supporting Practice Change for Collaborative Care
Williams, Mark D. , Ratzliff, Anna , Ratzliff, Anna H

Focus | July 18, 2017 | Volume: 15 | Issue: 3 | Pages: 294-297

10.1176/appi.focus.20170009 | PMID 31975861 Get It